BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals Inc. (VGX) announced today that it has signed a license agreement with the University of Pennsylvania covering novel DNA Vaccines and Therapeutics. Under the terms of the agreement VGX will have exclusive worldwide rights to develop a number of DNA plasmids and constructs with potential for the treatment and/or prevention of HIV, HCV, HPV and Influenza. This new agreement broadens the existing relationship between the two organizations. VGX was founded as a start-up in 2000 based on technology licensed from the University of Pennsylvania. VGX has previously licensed a number of product candidates and technology from the University of Pennsylvania and currently sponsors clinical research and basic research projects at the University.
